药物之间的相互作用1329045个记录(本栏目收费,不能展示细节,电话13136136841)
药物之间的相互作用
Zuclopenthixol
MYO-029
The risk or severity of adverse effects can be increased when MYO-029 is combined with Trastuzumab deruxtecan.
Zuclopenthixol
RI 624
The risk or severity of adverse effects can be increased when RI 624 is combined with Trastuzumab deruxtecan.
Zuclopenthixol
TNX-901
The risk or severity of adverse effects can be increased when TNX-901 is combined with Trastuzumab deruxtecan.
Zuclopenthixol
PRO-542
The risk or severity of adverse effects can be increased when PRO-542 is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Ustekinumab
The risk or severity of adverse effects can be increased when Ustekinumab is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Veltuzumab
The risk or severity of adverse effects can be increased when Veltuzumab is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Farletuzumab
The risk or severity of adverse effects can be increased when Farletuzumab is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Ramucirumab
The risk or severity of adverse effects can be increased when Ramucirumab is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Enokizumab
The risk or severity of adverse effects can be increased when Enokizumab is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Iratumumab
The risk or severity of adverse effects can be increased when Iratumumab is combined with Trastuzumab deruxtecan.
Zuclopenthixol
AMG 108
The risk or severity of adverse effects can be increased when AMG 108 is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Otelixizumab
The risk or severity of adverse effects can be increased when Otelixizumab is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Briakinumab
The risk or severity of adverse effects can be increased when Briakinumab is combined with Trastuzumab deruxtecan.
Zuclopenthixol
NAV 1800
The risk or severity of adverse effects can be increased when NAV 1800 is combined with Trastuzumab deruxtecan.
Zuclopenthixol
XTL-001
The risk or severity of adverse effects can be increased when XTL-001 is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Obiltoxaximab
The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Girentuximab
The risk or severity of adverse effects can be increased when Girentuximab is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Rozrolimupab
The risk or severity of adverse effects can be increased when Rozrolimupab is combined with Trastuzumab deruxtecan.
Zuclopenthixol
CR002
The risk or severity of adverse effects can be increased when CR002 is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Bavituximab
The risk or severity of adverse effects can be increased when Bavituximab is combined with Trastuzumab deruxtecan.